How many units is 0.25 mg of semaglutide depends on your vial's concentration. At the most common 5 mg/ml concentration, 0.25 mg of semaglutide equals 5 units on a U100 insulin syringe. If your vial is 2.5 mg/ml, 0.25 mg equals 10 units. At 10 mg/ml, 0.25 mg equals 2.5 units, which is very small and harder to draw precisely. The 0.25 mg dose is the FDA-approved starting dose for both Ozempic and Wegovy.

Checkout this GLP-1 dose calculator for better insights.

Quick Answer Table: 0.25 mg Semaglutide to Units

The 0.25 mg dose is the standard starting dose used during the first 4 weeks of semaglutide therapy.

Concentration

Volume Needed

Units on U100 Syringe

2.5 mg/ml

0.1 ml

10 units

5 mg/ml (most common)

0.05 ml

5 units

10 mg/ml

0.025 ml

2-3 units (round)

Here is what to know up front about 0.25 mg semaglutide units. This is the semaglutide starting dose units used for the first 4 weeks of FDA-approved therapy with both Ozempic and Wegovy, per the FDA Wegovy prescribing information. At the most common 5 mg/ml concentration, this small dose equals just 5 units on a U100 insulin syringe. The 0.25 mg dose primes the body for higher doses with minimal GI side effects. For broader context on semaglutide titration, see compounded semaglutide dosage chart.

The Math: How We Calculated This

The formula for compounded semaglutide 0.25mg to units is:

Units = (mg dose ÷ concentration in mg/ml) × 100

Worked example at 5 mg/ml (most common):

0.25 mg ÷ 5 mg/ml = 0.05 ml 0.05 ml × 100 = 5 units on a U100 insulin syringe

At 2.5 mg/ml: 0.25 ÷ 2.5 = 0.1 ml = 10 units

At 10 mg/ml: 0.25 ÷ 10 = 0.025 ml = 2.5 units (round to 2 or 3)

The 0.25mg to units conversion gives small unit counts. The 2.5 mg/ml concentration provides the best precision for the starting dose, while 10 mg/ml is harder to read at this small volume.

Why the Starting Dose Is So Small

The 0.25 mg starting dose is intentionally small. Semaglutide can cause significant nausea, vomiting, and other GI side effects, especially in the first few weeks of therapy. The starting dose primes the body's GLP-1 receptors with minimal side effects, allowing patients to adjust before moving to therapeutic doses.

The semaglutide 0.25 mg dose:

  • Is not intended as a long-term therapeutic dose

  • Provides minimal weight loss or glycemic effects

  • Reduces nausea and other GI symptoms compared to starting at higher doses

  • Is used only for the first 4 weeks of therapy

After 4 weeks at 0.25 mg, patients typically move to 0.5 mg for weeks 5 to 8, then continue titrating up to the maintenance dose.

How to Draw 0.25 mg Semaglutide

The semaglutide 0.25 mg syringe choice depends on concentration.

At 5 mg/ml (5 units): Use a 0.3 ml insulin syringe with 1-unit markings. The 5 unit mark sits near the bottom of the barrel. The wide line spacing on the 0.3 ml syringe makes this small dose easy to draw precisely.

At 2.5 mg/ml (10 units): Use a 0.3 ml insulin syringe. The 10 unit mark is in the middle of the barrel. Easier to read than 5 units at 5 mg/ml.

At 10 mg/ml (2.5 units): Very small dose. Use a 0.3 ml insulin syringe and target the 2 or 3 unit mark. The half-unit precision is not achievable on standard syringes, so the dose will be slightly off. Some pharmacies discourage this concentration for starting doses.

For full guidance on syringe sizes, see how to read insulin syringe units.

Common Mistakes With 0.25 mg Conversion

Drawing 25 units instead of 5 units. Writing the dose as 0.25 mg can lead to confusion with the unit count. At 5 mg/ml, 0.25 mg is 5 units, not 25 units. Drawing 25 units would deliver 1.25 mg, 5 times the intended starting dose. This significant overdose could cause severe nausea and vomiting.

Skipping the 0.25 mg starting dose. Some patients try to start at 0.5 mg or higher. The 4-week titration step at 0.25 mg exists to reduce GI side effects. Skipping can cause severe nausea, vomiting, and dehydration.

Using a 10 mg/ml vial for 0.25 mg. At 10 mg/ml, the starting dose is only 2.5 units, which is hard to draw precisely on a standard U100 syringe. Most compounding pharmacies dispense at 2.5 mg/ml or 5 mg/ml for patients starting therapy.

Continuing the starting dose too long. The 0.25 mg dose is for the first 4 weeks only. Staying at this dose beyond 4 weeks delays reaching the therapeutic dose range. Talk with your physician if GI side effects make titration difficult.

Frequently Asked Questions

The ml depends on concentration. At 2.5 mg/ml, 0.25 mg = 0.1 ml. At 5 mg/ml (most common), 0.25 mg = 0.05 ml. At 10 mg/ml, 0.25 mg = 0.025 ml. These are all very small volumes that require careful measurement.

Yes. Both FDA-approved Ozempic (type 2 diabetes) and Wegovy (weight loss) start at 0.25 mg once weekly for the first 4 weeks of therapy. This starting dose helps the body adjust to GLP-1 effects and reduces nausea, vomiting, and other GI side effects.

The 5 mg/ml concentration is most common, where 0.25 mg = 5 units. The 2.5 mg/ml concentration provides better precision for small doses (0.25 mg = 10 units). The 10 mg/ml concentration is too dilute for accurate starting-dose measurement.

Yes. A 0.3 ml insulin syringe is ideal for the 0.25 mg starting dose. The 1-unit markings give precise reading for the small unit counts (5 to 10 units typically). A larger 1 ml syringe is harder to read at the bottom where small doses sit.

At 10 mg/ml, 0.25 mg = 2.5 units. Since insulin syringes do not have half-unit markings, round to 2 or 3 units. The 0.5 unit difference at 10 mg/ml represents 0.05 mg, which is meaningful at the starting dose. Most pharmacies use 2.5 mg/ml or 5 mg/ml to avoid this issue.

The FDA-approved titration schedule recommends 4 weeks at 0.25 mg before moving to 0.5 mg. Some patients with significant GI side effects stay at 0.25 mg longer before progressing. Your physician may extend the starting dose if needed. The 0.25 mg dose is not intended as a long-term therapeutic dose.